Lonvi Bio — PCC1 Senolytic Platform

Procyanidin C1 (PCC1) is the polyphenol most strongly linked in current literature to clearing senescent — or "zombie" — cells, the aged cells that drive chronic systemic inflammation and biological ageing. Standard grape-seed and apple extracts contain only 0.1–0.6% PCC1 and are poorly absorbed.

Lonvi has pioneered an extraction method that concentrates active PCC1 to roughly 20%, and engineered a phytosomal delivery shield that improves absorption several-fold, while driving extraction cost down by over 95%. A single three-day regimen is presented as the PCC1 equivalent of three metric tons of grapes. Early pre-clinical human work reported 25–75% reductions in SASP inflammatory markers and senescent markers such as IL-6, IL-8, p21 and SA-β-gal; results remain under peer review.

Revenue comes from a consumer senolytic protocol plus research reagents — senescent cell detection kits and senolytic and senomorphic compound libraries sold to laboratories.